ST
Sling Therapeutics, Inc.
United States · Biotech
A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease.
An oral approach under clinical evaluation
Sling's lead candidate, linsitinib, inhibits the insulin-like growth factor 1 receptor, a target involved in thyroid eye disease. The company is evaluating the small molecule as an oral treatment option.
In September 2026, Sling announced that the first patients had been dosed in its global Phase 3 ORBIT trial. The programme remains in clinical development; the company is based in Ann Arbor, Michigan.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series C | $123M | Forbion — LeadSectoral Asset Management — ParticipantTPG Life Sciences Innovations — Participant |